Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06118372 · ClinicalTrials.gov registry record · Phase 1
Recombinant vWF Concentrate and ECMO
A Phase 1 study of Bleeding Disorder, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06118372 is a Phase 1 study of Bleeding Disorder that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 12 participants, below the 1,267-participant average among 3 other Bleeding Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06118372, a Phase 1 study of Bleeding Disorder, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Adult patients on extracoporeal membrane oxygenation (ECMO) frequently experience bleeding, which is in part caused by acquired von Willebrand syndrome (vWS). Prior in vitro studies have shown that the addition of recombinant von Willebrand Factor (vWF) to ECMO patient blood samples, normalizes platelet adhesion and thrombus formation. This study is a phase I study, where adult ECMO patients with refractory bleeding will be treated with recombinant vWF a single time. The primary objectives are to evaluate the safety, tolerability, and pharmacokinetics of recombinant vWF in adult ECMO patients.
Conditions Studied
Interventions
- DRUG Recombinant von Willebrand Factor
Study Locations (1)
Virginia
- UVA Hospital - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-10-03 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06118372
The ClinicalTrials.gov registry entry for NCT06118372 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,267-participant average among 3 other Bleeding Disorder trials with a reported enrollment target (99% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bleeding Disorder appearing as the primary indexed condition, and to 1 intervention - of which Recombinant von Willebrand Factor is the first listed.
NCT06118372 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06118372 about?
NCT06118372 is a clinical study titled "Recombinant vWF Concentrate and ECMO". Adult patients on extracoporeal membrane oxygenation (ECMO) frequently experience bleeding, which is in part caused by acquired von Willebrand syndrome (vWS). Prior in vitro studies have shown that the addition of recombinant von Willebrand Factor (vWF) to ECMO patient blood samples, normalizes plat...
What is the current status of trial NCT06118372?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-10-03. Estimated completion is 2027-02-28.
What conditions does trial NCT06118372 study?
This clinical trial studies the following conditions: Bleeding Disorder.
What interventions are being tested in trial NCT06118372?
The interventions under investigation include: Recombinant von Willebrand Factor (DRUG).
Who is sponsoring clinical trial NCT06118372?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06118372 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bleeding Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.